Studies were required to report at least one of the following outcomes: change in body weight, BMI, waist circumference, or HOMA-IR
You can read the full article at Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events The usage of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has been linked to adverse events (AEs)
As these medications reduce overall energy intake, individuals are consuming fewer calories with estimates placing this reduction between 16 and 39%, or about 700 calories per day on average (Hristakeva et al., 2024)
A quality GLP-1 travel case is essential
When to Seek Medical Advice About Swollen Lymph Nodes Whilst many cases of lymphadenopathy resolve spontaneously as minor infections clear, certain features warrant prompt medical evaluation
Mounjaro and Wegovy are both weight loss injections available with a prescription in the UK